On May 9, 2024, the Syros Pharmaceuticals, Inc. agreed to amend its Loan Agreement with Oxford Finance LLC. The amendment will increase the amount of term loans available to Syros from $40 million to $100 million with tranches totaling $40.0 million in the aggregate becoming available upon the achievement of certain clinical development, regulatory and equity-raising milestones, and $20.0 million becoming available at Oxford's discretion. In addition, Oxford will extend the interest only period from September 1, 2024 to November 1, 2025 with further extensions to as late as November 1, 2026 upon achievement of certain milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | +0.60% | -11.50% | -35.82% |
May. 14 | Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.82% | 134M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- SYRS Stock
- News Syros Pharmaceuticals, Inc.
- Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC